Sequential anti-osteoporotic therapy with teriparatide and alendronate optimizes outcomes of percutaneous vertebroplasty in acute osteoporotic vertebral fractures: a 12-month prospective cohort study.

ABSTRACT:

Background

Percutaneous vertebroplasty (PVP) is widely utilized for managing osteoporotic vertebral compression fractures (OVCFs), yet its long-term efficacy remains controversial. Previous studies have overlooked the potential impact of anti-osteoporotic medications on PVP outcomes. This study evaluates the clinical benefits of PVP combined with alendronate (ALN) or sequential teriparatide (TPTD)/ALN therapy in postmenopausal women with acute OVCFs.

Method

In this prospective cohort study, 216 postmenopausal women with fresh OVCFs were allocated to four groups based on patients' preference: ALN monotherapy (ALN group), PVP combined with ALN therapy (ALN + PVP group), sequential therapy with TPTD for 6 months followed by ALN (TPTD group), and PVP combined with sequential TPT

SUBMITTER: Xie Y 

PROVIDER: S-EPMC12573811 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature